Welcome to Shuangcheng Pharma
Founded in 2000, Hainan Shuangcheng Pharmaceuticals Co., Ltd (HNSP) is a publicly-traded company and engaged in development, manufacturing and marketing of both APIs and drug products. Having excellent know-how in peptide chemistry, HNSP is a leader in the field of peptide manufacture, with current U.S. FDA and AIFA (Italian Medicines Agency) approved production.
The company is headquartered near Haikou airport on Hainan Island, China with R&D and manufacturing facilities at the Haikou site, and is building new facilities in Ningbo, about 1.5 hours’ drive from Shanghai’s Pudong Airport (PVG). HNSP also has a subsidiary company in Italy.
HNSP is rapidly expanding in China and elsewhere around the world, and is presently seeking collaborations and partnerships with pharmaceutical companies in the U.S., Europe and other regions.
- Memantine Hydrochloride Tablets Receives US FDA MA approval2020-04-28
- Ningbo Shuangcheng Passes U.S. FDA Inspection 2020-04-28
- Hainan Shuangcheng Passes U.S. FDA Inspection2020-04-28
- Bivalirudin for Injection Receives U.S. FDA Final Approval2020-04-28
- Shuangcheng Donates Medical Products to Support Fighting of COVID-192020-04-28
- Bivalirudin for Injection First Launched in U.S.2020-03-08
- Pregabalin Capsule ANDA Approved by U.S. FDA2019-10-08
- Hainan Shuangcheng Passes U.S. FDA Inspection2019-07-01
- Eptifibatide DMF Passes U.S. FDA Review2017-11-02